ID | 63410 |
JaLCDOI | |
フルテキストURL | |
著者 |
Higashionna, Tsukasa
Department of Pharmacy, Okayama University Hospital
Ushio, Soichiro
Department of Pharmacy, Okayama University Hospital
Esumi, Satoru
Department of Pharmacy, Okayama University Hospital
Murakawa, Kiminaka
Department of Pharmacy, Okayama University Hospital
Kitamura, Yoshihisa
Department of Pharmacy, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
抄録 | Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN.
|
キーワード | febrile neutropenia
cefozopran
cefepime
lung cancer
retrospective
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2022-04
|
巻 | 76巻
|
号 | 2号
|
出版者 | Okayama University Medical School
|
開始ページ | 167
|
終了ページ | 172
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |